BRPI0507612A - análogos exibindo inibição de proliferação de célula e métodos para fabricação e uso destes - Google Patents

análogos exibindo inibição de proliferação de célula e métodos para fabricação e uso destes

Info

Publication number
BRPI0507612A
BRPI0507612A BRPI0507612-9A BRPI0507612A BRPI0507612A BR PI0507612 A BRPI0507612 A BR PI0507612A BR PI0507612 A BRPI0507612 A BR PI0507612A BR PI0507612 A BRPI0507612 A BR PI0507612A
Authority
BR
Brazil
Prior art keywords
cell proliferation
methods
making
inhibition
exhibiting inhibition
Prior art date
Application number
BRPI0507612-9A
Other languages
English (en)
Inventor
Duane D Miller
James T Dalton
Veeresa Gududuru
Eunju Hurh
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Publication of BRPI0507612A publication Critical patent/BRPI0507612A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

ANáLOGOS EXIBINDO INIBIçãO DE PROLIFERAçãO DE CéLULA E MéTODOS PARA FABRICAçãO E USO DESTES Os análogos que exibem a inibição da proliferação de célula são fornecidos. Os métodos de fabricação dos mesmos são incluídos também. Os análogos podem ser usados tratar condições cancerígenas tais como o câncer de próstata, câncer de mama e câncer ovariano.
BRPI0507612-9A 2004-02-11 2005-02-11 análogos exibindo inibição de proliferação de célula e métodos para fabricação e uso destes BRPI0507612A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54372404P 2004-02-11 2004-02-11
US55580304P 2004-03-24 2004-03-24
PCT/US2005/004759 WO2005086638A2 (en) 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0507612A true BRPI0507612A (pt) 2007-07-03

Family

ID=34976061

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507612-9A BRPI0507612A (pt) 2004-02-11 2005-02-11 análogos exibindo inibição de proliferação de célula e métodos para fabricação e uso destes

Country Status (8)

Country Link
EP (1) EP1723127A4 (pt)
JP (1) JP2007522247A (pt)
AU (1) AU2005220705A1 (pt)
BR (1) BRPI0507612A (pt)
CA (1) CA2559333A1 (pt)
EA (1) EA200601471A1 (pt)
IL (1) IL177444A0 (pt)
WO (1) WO2005086638A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395146B1 (ko) * 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2014066613A2 (en) * 2012-10-26 2014-05-01 Zhejiang University Sphingolipid metabolite mimetics
KR20160003652A (ko) 2013-03-15 2016-01-11 캔써 리써치 테크놀로지, 엘엘씨 감마―글루타밀 주기 조절 방법 및 조성물
WO2023170024A1 (en) * 2022-03-11 2023-09-14 University Of Copenhagen Camk2 modulators and their use in medicine
CN115894398B (zh) * 2022-12-02 2024-03-12 青岛科技大学 一种含氟噻唑酰胺类杀虫杀螨剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1017435B (zh) * 1987-03-24 1992-07-15 日本化学医药株式会社 新的甘油衍生物的制备方法
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
FR2678938B1 (fr) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
FR2700168B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen

Also Published As

Publication number Publication date
WO2005086638A2 (en) 2005-09-22
EA200601471A1 (ru) 2007-10-26
CA2559333A1 (en) 2005-09-22
IL177444A0 (en) 2006-12-10
JP2007522247A (ja) 2007-08-09
EP1723127A4 (en) 2009-10-28
WO2005086638A3 (en) 2005-11-24
EP1723127A2 (en) 2006-11-22
AU2005220705A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
GT200500237A (es) Derivados de pirimidina
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
CL2010001624A1 (es) Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto.
ATE408412T1 (de) Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration
CL2012002844A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende; y su uso en el tratamiento de un trastorno proliferativo de celulas tal como cancer (divisional solicitud nº 311-07).
NI201500088A (es) Inhibidores de histona desmetilasa
CL2008002982A1 (es) Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata.
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
MX346924B (es) Compuestos de diarilhidantoina.
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
MXPA05011755A (es) Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.
MX377405B (es) Compuestos para el tratamiento de cáncer.
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
MX336675B (es) Cribado para compuestos anticancerigenos utilizando actividad de netrina-1.
BRPI0715176A8 (pt) compostos de heteroarila utéis como inibidores de enzimas de ativação e1
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
MX336339B (es) Nuevo uso antitumoral de cabazitaxel.
WO2013152120A3 (en) Compositions and methods for promoting intestinal stem cell function
CR11412A (es) Inhibidores de cinesina como productos terapeuticos para el cancer
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.